AATS Annual Meeting 2015 | Seattle, WA | April 27, 2015 Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement.

Slides:



Advertisements
Similar presentations
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Advertisements

Health-Related Quality of Life After Transcatheter vs. Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis Results From.
ACC 2015 Jae K. Oh, MD On Behalf of the US CoreValve Investigators Remodeling of Self-Expanding Transcatheter Aortic Valve Is Responsible for Regression.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
THE RISE OF NEW TECHNOLOGIES FOR AORTIC VALVE STENOSIS: A PROPENSITY-SCORE ANALYSIS FROM TWO MULTICENTER REGISTRIES COMPARING SUTURELESS AND TRANS-CATHETER.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
The PARTNER Stroke Substudy Writing Group* On behalf of The PARTNER Trial Investigators and Patients Transcatheter (TAVR) versus Surgical (AVR) Aortic.
Long-term Benefits of Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus on Right Ventricular Function Brent Keeling MD 1, Bradley G. Leshnower.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.
Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Transcather Aortic Valve Replacement Using the Self-Expanding Bioprosthesis: First Report Using STS/ACC Transcatheter Valve Therapy Registry CoreValve.
Postoperative Delirium is Associated with Increased Operative and One Year Mortality in Patients Treated with Surgical and Transcatheter Aortic Valve Replacement.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
GENDER DISPARITIES AMONG PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT Michael A. Gaglia, Jr.; Michael J. Lipinski; Rebecca Torguson; Jiaxiang.
Techniques in Transapical AVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:
Long-term Survival, Valve Durability, and Reoperation for Four Aortic Root + Ascending Procedures Lars G. Svensson, Saila T. Pillai, Jeevanantham Rajeswaran,
TCT 2015 | San Francisco | October 15, 2015 Howard C. Herrmann, MD on behalf of The PARTNER II Trial Investigators SAPIEN 3: Evaluation of a Balloon- Expandable.
The Reoperative Aortic Root: Degenerative Failure vs. Infectious Destruction – Outcomes of The “True Redo-Root” Reconstruction Rita K. Milewski, Arminder.
G. Michael Deeb, MD On Behalf of the US Pivotal Trial Investigators 3-Year Results From the US Pivotal High Risk Randomized Trial Comparing Self-Expanding.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat.
G. Michael Deeb, MD On Behalf of the CoreValve US Investigators
The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Transcatheter Aortic Valve Replacement Andres M. Pineda MD, J. Kevin.
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
New Data from The PARTNER Trial
Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients Vinod H. Thourani, MD on behalf of the PARTNER Trial Investigators Professor.
Transcatheter (TAVR) versus Surgical (AVR) Aortic Valve Replacement: Incidence, hazard, determinants, and consequences of neurological events in the PARTNER.
Volume 385, Issue 9986, Pages (June 2015)
Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators
Are we ready to perform TAVI in Intermediate Risk Patients?
Updates From NOTION: The First All-Comer TAVR Trial
J. Matthew Brennan, MD, MPH Duke University School of Medicine
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
TAVR Requirements for the Cath Lab
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
University of Pennsylvania
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Updates From SURTAVI in Intermediate Risk Patients
Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,
Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Insights from the NCDR® STS/ACC TVT Registry.
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Annual Outcomes With Transcatheter Valve Therapy
Annual Outcomes With Transcatheter Valve Therapy
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Graft Operation: A PARTNER Trial Subgroup Analysis 
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
Lars G. Svensson, MD, PhD, David H. Adams, MD, Robert O
Impact of Preoperative Chronic Kidney Disease in 2,531 High-Risk and Inoperable Patients Undergoing Transcatheter Aortic Valve Replacement in the PARTNER.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons.
Appropriate patient selection or health care rationing
Transapical Aortic Valve Replacement for Severe Aortic Stenosis: Results From the Nonrandomized Continued Access Cohort of the PARTNER Trial  Todd M.
Enhancing the Value of Population-Based Risk Scores for Institutional-Level Use  Sajjad Raza, MD, Joseph F. Sabik, MD, Jeevanantham Rajeswaran, PhD, Jay.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Vinod H. Thourani, MD, Hanna A
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Applying Classification of Recommendation and Level of Evidence
Conventional redo biological valve replacement over 20 years: Surgical benchmarks should guide patient selection for transcatheter valve-in-valve therapy 
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

AATS Annual Meeting 2015 | Seattle, WA | April 27, 2015 Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Szeto, MD on behalf of The PARTNER Trial Investigators and The PARTNER Publications Office

Investigator, Steering committee member of the PARTNER trialInvestigator, Steering committee member of the PARTNER trial Edwards LifesciencesEdwards Lifesciences Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Disclosure Statement of Financial Interest Wilson Y. Szeto, MD

Background Surgical aortic valve replacement (SAVR) is being challenged by transcatheter aortic valve replacement (TAVR) for patients considered at high surgical risk.Surgical aortic valve replacement (SAVR) is being challenged by transcatheter aortic valve replacement (TAVR) for patients considered at high surgical risk. There is increasing pressure on surgeons and institutions to improve quality metrics and outcomes while reducing cost of medical care.There is increasing pressure on surgeons and institutions to improve quality metrics and outcomes while reducing cost of medical care. Surgeons considering SAVR in high risk patients risk failing quality metrics.Surgeons considering SAVR in high risk patients risk failing quality metrics.

Objectives / Questions The Placement of Aortic Transcatheter Valves (PARTNER) trial provides insight into outcomes after surgical AVR in high-risk patients at extreme of traditional indications for SAVR. 1) Are surgical outcomes after high risk SAVR accurately predicted by current national benchmarks? 2) Is intermediate term survival after high risk AVR commensurate with that of the matched general population seen in previous studies? 3) Is there a subset of elderly patients whose risk of mortality after SAVR is exceptionally high (with survival worse than treatment without AVR, i.e. futility)?

Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High-Risk AVR Candidate 3,105 Total Patients Screened ASSESSMENT: High-Risk AVR Candidate 3,105 Total Patients Screened Cohort B (Inoperable) n=358 Cohort B (Inoperable) n=358 Cohort A (High Surgical Risk) n=699 Cohort A (High Surgical Risk) n=699 Did not undergo SAVR (n=38) -Died before procedure: 5 -Deteriorated before procedure: 5 -Refused: 17 -Withdrew: 11 Did not undergo SAVR (n=38) -Died before procedure: 5 -Deteriorated before procedure: 5 -Refused: 17 -Withdrew: 11 Crossover from TAVR to Medical Therapy: 2 Allocated to SAVR n=351 Allocated to SAVR n=351 Allocated to Medical Therapy n=179 Allocated to Medical Therapy n=179 Received Medical Therapy n=181 Received Medical Therapy n=181 ReceivedSAVR n=351 ReceivedSAVR n=351 Allocated to TAVR (n=348) Allocated to TAVR (n=348) Allocated to TAVR (n=179) Allocated to TAVR (n=179)

Patient Population 699 patients with severe symptomatic AS were enrolled into PARTNER 1A from patients with severe symptomatic AS were enrolled into PARTNER 1A from Of the 351 patients randomized to SAVR, 313 underwent AVR (as treated cohort).Of the 351 patients randomized to SAVR, 313 underwent AVR (as treated cohort). –28 patients withdrew / refused therapy –10 patients deteriorated to an inoperable status 181 patients in PARTNER 1B (inoperable cohort) randomized to medical therapy were used as reference for survival without valve replacement.181 patients in PARTNER 1B (inoperable cohort) randomized to medical therapy were used as reference for survival without valve replacement.

Methodology Procedural outcome and primary safety endpoints were compared to national quality benchmarks for SAVR defined according to the STS Database Version 2.61.Procedural outcome and primary safety endpoints were compared to national quality benchmarks for SAVR defined according to the STS Database Version Intermediate term survival comparison with matched general population was performed using 2008 US life tables.Intermediate term survival comparison with matched general population was performed using 2008 US life tables. Incremental risk factors for mortality were identified from 102 possible risk factors.Incremental risk factors for mortality were identified from 102 possible risk factors.

Patient Characteristics (1) No. (%) or Mean ± SD Demographics Female 134 (43) Age (y) 84 ± 6.3 Body Mass Index (kg/m 2 ) 27 ± 5.7 Symptoms NYHA Class 3 or (95) Predicted operative mortality By benchmark available at time of enrollment (%) 12 ± 3.4 Cardiac Comorbidities Coronary Artery Disease 241 (77) Previous MI 90 (29) Atrial Fibrillation 69 (22)

Patient Characteristics (2) No. (%) or Mean ± SD Non-Cardiac Comorbidities Peripheral Arterial Disease 210 (67) CVD 108 (35) Diabetes 128 (41) Chronic Pulmonary Disease 147 (47) Renal Disease 69 (22) Hepatic Disease 9 (2.9) Previous Procedures PCI 101 (32) CABG 140 (45) Pacemaker 70 (22) Echocardiographic Characteristics AV peak velocity (cm/sec) 422 ± 70 AV area (cm 2 ) 0.64 ± 0.19 AV mean gradient (mmHg) 43 ± 14 Ejection fraction (%) 53 ± 12

Operative Details / Variables (1) No. (%) or Mean ± SD Incision Full sternotomy 243 (78) Partial sternotomy 51 (16) Thoracotomy 18 (5.8) Aortic valve prosthesis Valve size (mm) (12) (40) (35) (12) (0.97)

Operative Details / Variables (2) No. (%) or Mean ± SD Prosthesis type Edwards Lifesciences Edwards Lifesciences 273 (87) St. Jude St. Jude 3 (0.95) Carbomedics mechanical Carbomedics mechanical 4 (1.3) Medtronic Medtronic 12 (3.8) Sorin Sorin 7 (2.2) Unspecified porcine Unspecified porcine 1 (0.32) Unspecified Unspecified 13 (4.2) Concomitant procedure Unanticipated CABG 21 (6.7) Support Aortic clamp time (min) 74 ± 29 Cardiopulmonary bypass time (min) 105 ± 41

Outcome Referenced to Contemporary STS Benchmarks OutcomeObserved No. (%) Expected Observed/Expected (68% CL) p Operative mortality 33 (10) 29 (9.3) 1.14 (1.01 – 1.29) 0.40 Stroke 8 (2.6) 11 (3.5) 0.73 (0.55 – 0.94) 0.40 Renal Failure 18 (5.8) 38 (12) 0.48 (0.38 – 0.60) Deep sternal wound infection 2 (0.64) 1.03 (0.33) 1.94 (0.91 – 3.1) 0.30 Postoperative length of stay > 14 days 83 (26) 56 (18) 1.48 (1.36 – 1.62) < OutcomeObserved No. (%) Expected Observed/Expected (68% CL) p Operative mortality 33 (10) 29 (9.3) 1.14 (1.01 – 1.29) 0.40 Stroke 8 (2.6) 11 (3.5) 0.73 (0.55 – 0.94) 0.40 Renal Failure 18 (5.8) 38 (12) 0.48 (0.38 – 0.60) Deep sternal wound infection 2 (0.64) 1.03 (0.33) 1.94 (0.91 – 3.1) 0.30 Postoperative length of stay > 14 days 83 (26) 56 (18) 1.48 (1.36 – 1.62) <0.0001

% Years Worse Survival Compared to Age Matched Population SAVR

Incremental Risk Factors for Mortality after SAVR Risk Factor Coefficient ± SE p Hazard Ratio (68% CL) Reliability (%) a Early decreasing hazard Previous CABG (less risk) ± (0.42 – 0.76) 88 Lower albumin b 7.0 ± n/a51 Longer aortic clamp time c 0.95 ± n/a60 Intermediate-term hazard Smaller BMI d 0.99 ± n/a64 History of cancer 0.86 ± (1.7 – 3.2) 59 Severe prosthesis- patient mismatch 0.77 ± (1.6 – 2.8) 86 a.Percent of times variables appeared in 1000 bootstrap models b.(1/albumin), inverse transformation c.Log (aortic clamp time/75), logarithmic transformation d.(25/BMI) 2, inverse squared transformation

% Years Prior CABG Yes No Survival

1 Year Survival - Albumin Albumin (g/dL) Survival (%)

Aortic Clamp Time (min) Survival (%) 1 Year Survival - Aortic Clamp Time

1 Year Survival - BMI Body Mass Index Survival (%)

% Years Cancer No Yes Survival

% Years Mismatch None/Mild Severe Moderate Survival

% Years SAVR Medical Therapy Survival: SAVR vs Medical Therapy

% Years SAVR Medical Therapy Survival Age = 70 BMI = 36 Albumin = 2.9 Cancer

% Years Medical Therapy SAVR Survival Age = 90 BMI = 27 Albumin = 3.04 Cancer

% Years Medical Therapy SAVR Survival Age = 86 BMI = 21 Cancer Previous CABG

Conclusions (1) PARTNER 1A SAVR outcome was similar to contemporary benchmarks, suggesting these benchmarks may underestimate risk across high risk profiles.PARTNER 1A SAVR outcome was similar to contemporary benchmarks, suggesting these benchmarks may underestimate risk across high risk profiles. PARTNER 1A SAVR patients had worse survival compared to matched US population, suggesting a less selected population with higher morbidities and risk profile.PARTNER 1A SAVR patients had worse survival compared to matched US population, suggesting a less selected population with higher morbidities and risk profile.

Conclusions (2) PARTNER 1A SAVR patients have improved survival compared to PARTNER 1B patients randomized to medical therapy, although a few selected risk profiles demonstrated the futility of SAVR with worse outcome.PARTNER 1A SAVR patients have improved survival compared to PARTNER 1B patients randomized to medical therapy, although a few selected risk profiles demonstrated the futility of SAVR with worse outcome. PARTNER selection criteria for SAVR may be more appropriate and realistic, thus reflecting the contemporary surgical management of severe aortic stenosis in high risk patients.PARTNER selection criteria for SAVR may be more appropriate and realistic, thus reflecting the contemporary surgical management of severe aortic stenosis in high risk patients.

Thank you to the dedicated study teams at all the PARTNER Sites! Special thanks to the participants in this writing group Lars G. Svensson Jeevanantham Rajeswaran John Ehrlinger Rakesh M. Suri Craig R. Smith Michael Mack D. Craig Miller Patrick M. McCarthy Joseph E. Bavaria Lawrence H. Cohn Paul J. Corso Robert A. Guyton Vinod H. Thourani Bruce W. Lytle Mathew R. Williams John G. Webb Samir Kapadia E. Murat Tuzcu David J. Cohen Hartzell V. Schaff Martin B. Leon Eugene H. Blackstone